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ABSTRACT 62 
Context 63 
Hyperthyroidism is associated with increased fracture risk, but it is not clear if lower TSH and higher free 64 
thyroxine (FT4) in euthyroid individuals are associated with fracture risk.  65 
Objective 66 
To evaluate the association of TSH and FT4 with incident fractures in euthyroid individuals.  67 
Design 68 
Individual participant data analysis. 69 
Setting 70 
Thirteen prospective cohort studies with inception between 1981 and 2002. 71 
Participants 72 
Adults with baseline TSH 0.45-4.49 mIU/L. 73 
Main Outcome Measures 74 
Primary outcome was incident hip fracture. Secondary outcomes were any, non-vertebral, and vertebral 75 
fractures. Hazard ratios (HR) with 95% confidence interval (CI) were adjusted for age and sex. For clinical 76 
relevance, we studied TSH according to five categories: 0.45-0.99mIU/L; 1.00-1.49mIU/L; 1.50-2.49mIU/L; 77 
2.50-3.49mIU/L; 3.50-4.49mIU/L (reference). FT4 was assessed as study-specific standard deviation increase, 78 
because assays varied between cohorts. 79 
Results 80 
During 659,059 person-years, 2,565/56,835 participants had hip fracture (4.5%; 12 studies with available data). 81 
The pooled adjusted HR (95%CI) for hip fracture was 1.25 (1.05-1.49) for TSH 0.45-0.99 mIU/L, 1.19 (1.01-82 
1.41) for TSH 1.00-1.49 mIU/L, 1.09 (0.93-1.28) for TSH 1.50-2.49 mIU/L, and 1.12 (0.94-1.33) for TSH 2.50-83 
3.49 mIU/L (P for trend = 0.004). Hip fracture was also associated with FT4 (HR 1.22, 95%CI 1.11-1.35 per 84 
one standard deviation increase in FT4). FT4 only was associated with any and non-vertebral fracture. Results 85 
remained similar in sensitivity analyses. 86 
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Conclusions  87 
Among euthyroid adults, lower TSH and higher FT4 are associated with an increased risk of hip fracture. These 88 
findings may help refine the optimal ranges of thyroid function tests.  89 
 90 
Registration: The protocol was published on PROSPERO (registration number CRD42016039125). 91 
Primary funding source: Swiss National Science Foundation (SNSF 320030-150025). 92 
 93 
  94 
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INTRODUCTION 95 
 96 
Overt hyperthyroidism is a well-known risk factor for fracture and is associated with decreased bone mineral 97 
density (BMD) (1). We recently showed that subclinical hyperthyroidism was also associated with increased 98 
fracture incidence (2). Thyroid hormones stimulate bone turnover acting directly and indirectly on osteoclasts 99 
and osteoblasts (3). Anabolic action is net during growth, but in adults, catabolic action leads to greater bone 100 
loss and higher fracture risk (3). Thyroid hormones might also decrease muscular strength and coordination, and 101 
increase the risk of fall (4, 5). Administering TSH reduces bone resorption and increases bone formation in post-102 
menopausal women monitored for thyroid cancer (6). Conversely, high TSH levels can degrade bone quality by 103 
increasing cortical, rather than trabecular bone.  104 
The reference range for thyroid function tests – “euthyroidism” – is defined by the 2.5 to 97.5 percentiles in an 105 
apparently healthy population. However, the studies from which TSH reference range was derived did not 106 
exclude participants with occult or underlying disease, e.g. those with positive anti-thyroid antibodies, which 107 
might bias the reference range towards higher TSH values (7, 8). In medicine, reference ranges can be derived 108 
from normative data, as for thyroid function tests, or preferably determining levels associated with important 109 
risks or outcomes, as for lipids, or blood pressure. 110 
TSH within the lower reference range has been associated with osteoporosis and fracture mostly in cross-111 
sectional studies of healthy post-menopausal women, but prospective data are limited and conflicting (5, 9-13). 112 
If we can better understand the association between TSH and health outcomes, we could make more accurate 113 
estimates of fracture risk, which would help refine thyroxine treatment targets. We hypothesized that lower TSH 114 
and higher FT4 in euthyroid participants were associated with increased risk of fractures. We therefore aimed to 115 
assess the association between TSH within the reference range, free thyroxine (FT4), and fracture risk by 116 
analyzing individual participant data (IPD) of population-based prospective cohort studies participating to the 117 
international Thyroid Studies Collaboration (2, 14).  118 
 119 
  120 
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METHODS 121 
 122 
Data source, searches and study selection  123 
The study protocol was registered on PROSPERO prior to study conduct (available on 124 
http://www.crd.york.ac.uk/PROSPERO; registration number: CRD42016039125). 125 
We updated our previous systematic literature search, which had identified in Ovid (MEDLINE) and EMBASE 126 
from inception to March 2015 all prospective cohorts of adults with baseline TSH and FT4 measurement and 127 
follow-up evaluation for incident fracture (2).Additionally, we searched for studies with participants with only 128 
euthyroidism, which may have been omitted in our initial search. Our Ovid (MEDLINE) and EMBASE search 129 
(until 05/19/2016) used following medical search terms: euthyroid, euthyroidism or normal TSH and fractures 130 
or osteoporosis. After retrieving studies according to titles and abstracts, two authors (C.E.A. and D.S.) 131 
independently reviewed full-texts to confirm study eligibility. Disagreements were resolved by consensus with a 132 
third author (N.R.). We also requested unpublished fracture data from all cohorts of the Thyroid Studies 133 
Collaboration (2, 14-17). Exclusion criteria were: 1) cohorts using first-generation TSH assays because these 134 
assays were not sensitive enough; 2) studies with only participants aged <18 years; 3) studies with only 135 
participants with thyroid medication (thyroxine or anti-thyroid drugs); 4) studies with only participants with 136 
TSH outside the reference range (<0.45mIU/L or >4.49mIU/L); and, 5) studies exclusively on participants after 137 
thyroid surgery. Agreement between reviewers was 100% (K =1.00). For the IPD analysis, we included all 138 
participants aged ≥18 years at enrollment with measured TSH at baseline evaluation, and fracture assessment, as 139 
defined below, at follow-up.140 
 141 
Data extraction and quality assessment 142 
If the cohorts identified met our eligibility criteria, they were invited to provide IPD. Each study was approved 143 
by its local ethics committee. All participants gave informed consent for the original studies. We collected 144 
information on demographics, anthropometrics, medications, other risk factors for fracture, history of thyroid 145 
disorders, BMD and incident fracture. 146 
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Risk of bias and study quality were independently assessed by C.E.A and D.S., using the following Newcastle-147 
Ottawa Quality Assessment Scale items (18): 1) cohorts selection; 2) cohorts representativeness; 3) 148 
ascertainment of exposure; 4) availability of relevant confounding factors for adjustment; 5) outcome 149 
assessment based on objective fracture assessment, with adjudication procedure for fractures other than hip; 6) 150 
length of follow-up; 7) adequacy of follow-up; 8) researchers/participants/physicians blinding to thyroid values; 151 
and, 9) publication status. In sensitivity analyses, we excluded cohorts that did not meet one or more item(s). 152 
 153 
Data synthesis and analysis 154 
Definition of thyroid function 155 
All included studies used a third-generation TSH radioimmunoassay. Details on the assays used for TSH and 156 
FT4 measurement are described in Supplemental Table 1. To maximize comparability, we used uniform TSH 157 
thresholds based on previously established thresholds, as done in previous reports of the Thyroid Studies 158 
Collaboration (2, 14). We defined euthyroidism as TSH 0.45-4.49 mIU/L. For clinical relevance, we separated 159 
TSH values into five categories: 0.45-0.99mIU/L; 1.00-1.49mIU/L; 1.50-2.49mIU/L; 2.50-3.49mIU/L; 3.50-160 
4.49mIU/L. The later was used as reference category because we hypothesized, based on our previous 161 
publication (2), that lower TSH might be associated with higher fracture risk.  Because of different FT4 162 
reference ranges across studies, we used standard deviation (SD) rather than specific cut-offs. FT4 was available 163 
for all but two studies in the euthyroid range (19, 20). 164 
 165 
Definition of outcomes 166 
Our primary outcome was incident hip fracture, including femoral neck, pertrochanteric, and subtrochanteric 167 
fractures, as previously defined (2). Briefly, we excluded pathologic (i.e. associated with metastasis or rare bone 168 
disease) and periprosthetic fractures. Any, non-vertebral and clinical vertebral incident fractures were secondary 169 
outcomes. We excluded 1) vertebral fractures diagnosed with only radiologic imaging to keep focus on clinical 170 
relevance; 2) cervical and sacral vertebral fractures because fractures at these locations are usually associated 171 
with trauma rather than osteoporosis. “Any fractures” included fractures at any location, except for skull, face, 172 
ankle, finger, or toe, since these are not related to osteoporosis. “Non-vertebral fractures” was the same as “any 173 
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fractures” except it excluded vertebral fractures. For any and non-vertebral fractures, we excluded cohorts that 174 
collected fracture data on only part of the skeleton. Supplemental Table 2 describes fracture definitions by 175 
study. 176 
 177 
Statistical analyses 178 
We used a shared frailty Cox regression model with random-effects at study level to conduct an IPD meta-179 
analysis, which used data from all included cohorts to assess the relationship of incident fractures with TSH 180 
categories and FT4, respectively (21, 22).  The random-effects accounted for the between-study variation caused 181 
by different definitions of TSH reference range across the studies, incorporating the extra uncertainty in the 182 
confidence intervals. We used Schoenfeld residuals to test the proportional-hazards assumption (23). Results 183 
were presented as hazard ratios (HR) compared to the reference category. Time-to-event was defined for each 184 
outcome from baseline TSH measurement to first fracture event. We adjusted primary analyses for age and sex, 185 
and then for other risk factors for fracture (body mass index [BMI], smoking, and history of diabetes), because 186 
they might mediate the association between thyroid function tests and fractures. We conducted following 187 
predefined sensitivity analyses: 1) excluding participants with thyroid medication (thyroxine or anti-thyroid 188 
medication) at baseline; 2) excluding participants with thyroid-altering medication at baseline (thyroid 189 
medication, oral corticosteroids, amiodarone, iodine); 3) excluding participants with anti-fracture medication at 190 
baseline (bisphosphonate, calcitonin, selective estrogen receptor modulator, parathyroid hormone); 4) including 191 
only studies with formal fracture adjudication; 5) including only studies that uniformly defined fractures (except 192 
for hip fracture, since it has a common definition and is rarely reported in error); 6) excluding cohorts with loss 193 
to follow-up rates >5%; 7) excluding participants who developed overt or subclinical thyroid dysfunction over 194 
time; 8) including only participants with TSH remaining within the reference range during follow-up; and 9) 195 
further adjusting for BMD, which reflects bone loss and may be a potential mediator between TSH or FT4 and 196 
incident fractures. In this last analysis, we used BMD as a continuous variable, and included only studies that 197 
used dual energy X-ray absorptiometry (DXA) devices with femoral neck BMD for hip fractures (available for 198 
six studies) (5, 10, 14, 24-26), lumbar spine BMD for vertebral fractures (available for one study) (10), and 199 
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whole body BMD for any fractures (available for one study) (10) . We conducted predefined stratified analyses 200 
by sex, age (<75 versus ≥75 years), and duration of follow-up (<5 versus ≥5 years).  201 
For the FT4 analysis, we used the whole range of FT4 values including only participants with TSH within the 202 
reference range. FT4 values were converted to ng/mL (12.87pmol/L = 1ng/mL). We used study-specific SD to 203 
assess fracture risk per one SD increase in FT4 because FT4 assays varied between cohorts (14). We performed 204 
the same sensitivity and stratified analyses as for TSH.  205 
We used STATA release 13.1 for all analyses (StataCorp LP, College Station, Texas). All tests were two-sided, 206 
at a 0.05 level of significance. 207 
 208 
 209 
210 
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RESULTS 211 
 212 
Our updated literature search identified nine additional reports (Supplemental Figure 1) (2). Eight of them 213 
concerned studies already identified in our previous search (2). The newly identified study (Study of 214 
Osteoporotic Fractures) (19) agreed to participate.  We excluded the Nagasaki Adult Health Study (27), because 215 
it used first-generation TSH assays, which have a low functional sensitivity (1mIU/L) (28). For the same reason, 216 
this study had been included in our previous work (2) only in the analysis on subclinical hypothyroidism, but 217 
not on subclinical hyperthyroidism (16).  We included thirteen studies (5, 10, 14, 17, 19, 25, 26, 29-34) from the 218 
USA, Europe, and Australia with 61,959 participants, and a median duration of follow-up of 12.1 years 219 
(interquartile range [IQR] 8.5-12.9), totaling 659,059 person-years. Median age was 64 (range 18-102) with 220 
60.5% women (Table 1). Median (IQR) TSH was 1.60mIU/L (1.10-2.30); 3.1% of participants used thyroid 221 
medication at baseline and 5.5% during follow-up; 17.7% had a TSH 0.45-0.99mIU/L, 24.8% 1.00-1.49mIU/L, 222 
37.4% 1.50-2.49mIU/L, 14.2% 2.50-3.49mIU/L and 5.9% 3.50-4.49mIU/L. Hip fracture occurred in 2,565 223 
participants (4.5%; 12 studies), any fracture in 2,333 (8.9%; 9 studies), non-vertebral fracture in 1,874 (8.5%; 9 224 
studies), and vertebral fracture in 263 (1.3%; 7 studies). Overall quality was good (Supplemental Table 3):  one 225 
study reported loss to follow-up >5% (5), four did not perform formal fracture adjudication (25, 29, 32, 33), and 226 
three had not published fracture data in a separate manuscript (17, 29, 33).  227 
Tests of the proportional-hazards assumption on the basis of Schoenfeld residuals indicated that assumptions 228 
were met for all analyses (P > 0.11 for all). 229 
 230 
Thyroid function and hip fractures 231 
Compared with the reference group (TSH 3.50-4.49mIU/L), pooled age- and sex-adjusted HR (95% CI) for hip 232 
fracture was 1.25 (1.05-1.49) for TSH 0.45-0.99mIU/L, 1.19 (1.01-1.41) for TSH 1.00-1.49mIU/L, 1.09 (0.93-233 
1.28) for TSH 1.50-2.49mIU/L, and 1.12 (0.94-1.33) for TSH 2.50-3.49mIU/L (P for trend 0.004, Figure 1). 234 
After adjusting for BMI, smoking status, and history of diabetes, HR (95% CI) was 1.24 (1.03-1.49) for TSH 235 
0.45-0.99mIU/L compared with the reference group, while HR (95%CI) for TSH 1.00-1.49mIU/L was 236 
somewhat attenuated and no longer statistically significant (1.15 [0.97-1.38]). The risk of hip fracture in 237 
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participants with TSH 0.45-0.99mIU/L remained significantly higher in all sensitivity analyses, and was even 238 
higher after adjusting for femoral neck BMD (Table 2). For TSH 1.00-1.49mIU/L, the risk of hip fractures 239 
remained significantly higher in all sensitivity analyses, except after adjusting for femoral neck BMD, or after 240 
excluding participants with thyroid-altering medication at baseline. This association remained not significant for 241 
TSH 1.50-2.49mIU/L, or TSH 2.50-3.49mIU/L. We found no significant interaction for sex, age, or duration of 242 
follow-up (Supplemental Figure 2), although confidence intervals were larger and point estimates smaller for 243 
age <75 years and follow-up <5 years. Conversely, there was significant interaction for publication status with a 244 
HR (95% CI) of 1.35 (1.13-1.61) for the ten studies that published risk of hip fracture associated with thyroid 245 
function tests in a separate manuscript, and 0.44 (0.21-0.90) for the two studies (17, 29) that did not previously 246 
publish hip fracture data associated with thyroid function tests in a separate article (P for interaction 0.0001, 247 
Supplemental Table 4). 248 
The HR (95% CI) for hip fracture was 1.24 (1.12-1.37) per one SD increase in FT4 (Figure 2). We found no 249 
significant interaction with sex, age, duration of follow-up, or publication status of hip fracture data (Figure 2, 250 
Supplemental Table 4), although point estimate was smaller when follow-up was <5 years. All sensitivity 251 
analyses yielded similar results (Table 2). In the 25,760 participants of the five cohorts with available data on 252 
thyroid function tests during follow-up (25, 29, 31-33), 146 (0.6%) participants developed subclinical 253 
hyperthyroidism and 46 (0.2%) overt hyperthyroidism. When we included only endogenous forms of thyroid 254 
dysfunction (i.e., participants without thyroxine use at baseline, N=25,049), 102 (0.4%) and 25 (0.1%) 255 
participants developed subclinical and overt hyperthyroidism, respectively. The HR (95% CI) for hip fracture 256 
for TSH 0.45-0.99 mIU/L compared with the reference group was 1.70 (1.13-2.57) in the sensitivity analysis 257 
including only participants with TSH remaining within the reference range (four cohorts with data on hip 258 
fracture and thyroid function tests during follow-up) (25, 29, 31, 32). 259 
 260 
Thyroid function and any, non-vertebral, and vertebral fractures 261 
For all TSH categories when compared with the reference group, we found no significant association for any, 262 
non-vertebral, or vertebral fractures (Supplemental Table 5). The HR (95% CI) per one SD increase in FT4 263 
was 1.08 (1.02-1.15) for any fracture, and 1.10 (1.03-1.18) for non-vertebral fracture. These associations 264 
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remained significant in most sensitivity analyses (Table 3), except when adjusting for BMD. Association 265 
between FT4 and vertebral fracture was not statistically significant, possibly because of the lower number of 266 
data (Table 3). We found no significant interaction in the analyses stratified by sex, age, duration of follow-up, 267 
or publication status for any of these fracture outcomes (Table 3, Supplemental Table 4).  268 
  269 
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DISCUSSION 270 
 271 
In this analysis of 61,959 euthyroid participants of thirteen prospective cohorts with 659,059 person-years of 272 
follow-up, lower TSH levels within the reference range were associated with increased risk of hip fracture, and 273 
higher FT4 levels with increased risk of hip, any, and non-vertebral fracture. 274 
While overt and subclinical hyperthyroidism have been associated with increased fracture risk (1, 2), previous 275 
studies on the relationship between TSH within the reference range and fracture risk had conflicting results. The 276 
Clalit Health Services, a large historical cohort study, found a borderline increased incidence of hip fracture 277 
with TSH 0.35-1.6mIU/L when compared with TSH 1.7-2.9mIU/L, but in women only (odds ratio [95%CI] 278 
1.28 [1.03-1.59]), while the association with other osteoporotic fractures was not statistically significant (11). A 279 
small cross-sectional study (N=129) found an association between low TSH and vertebral fracture (12). The 280 
Cardiovascular Health Study found no significant association between TSH within the reference range or FT4 281 
assessed as continuous variables and hip fracture (13), but, consistent with our findings, curves bent with an 282 
increased fracture risk for TSH <1.5 mIU/L and for FT4 >1.4 ng/mL. Our thorough IPD analysis across multiple 283 
prospective cohorts confirms the association between low TSH and hip fractures, and an association between 284 
high FT4 and all but vertebral fractures in participants with TSH within the reference range, suggesting that 285 
even a modest increase in thyroid hormone levels among euthyroid adults is associated with higher fracture risk. 286 
Our study was strengthened, first, by an IPD analysis that allowed us to standardize the definitions of predictors 287 
and outcomes, adjust for similar potential confounders, and avoid aggregation bias for subgroup analyses. This 288 
was the best way to perform time-to-event analysis. Second, our study is the largest to assess fracture risk in 289 
prospective cohorts with TSH within the reference range. Third, we included all international prospective 290 
cohorts available on this topic, since all the studies we identified agreed to participate.  291 
Our study had several limitations. First, our population consisted mostly of Caucasians and included few young 292 
adults. Second, thyroid function tests were performed only at baseline in most cohorts, so we may have included 293 
adults who later developed subclinical or overt thyroid dysfunction. However, our sensitivity analysis including 294 
only participants with persistent TSH within the reference range yielded an even stronger association between 295 
low TSH and hip fracture. In addition, other participants may have had a non-thyroidal illness, a potential cause 296 
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of suppressed TSH; however, the prevalence of non-thyroidal illness was likely low as we only studied 297 
community-dwelling adults. Third, fractures were adjudicated in nine of thirteen cohorts, and we could not 298 
uniformly define each fracture type across all cohorts. Nevertheless, sensitivity analyses limited to cohorts with 299 
the most uniform facture definitions or adjudicated fracture yielded similar results. Fourth, we did not know 300 
fracture mechanism, but we excluded pathological fractures and fracture locations typically not associated with 301 
osteoporosis to reduce bias related to traumatic fractures. Fifth, data on fractures other than hip location were 302 
available in a more limited number of studies, reducing the number of outcomes and the related power to 303 
identify associations. Sixth, we had no information on other factors that may have influenced bone integrity or 304 
accounted for variations in circulating TSH or FT4, such as nutrition or deiodinase activities. Finally, thyroid 305 
antibodies were not systematically measured and their potential impact on bone metabolism could not be 306 
assessed. 307 
Our findings may have two important clinical implications. First, TSH reference range is still a matter of debate 308 
(35). TSH reference range was indeed defined in a population that included persons with occult or underlying 309 
thyroid disease (7, 8). TSH between 0.4 and 2.5mIU/L is associated with a lower incidence of thyroid 310 
dysfunction (36), but previous studies showed various adverse outcomes associated with subclinical thyroid 311 
dysfunction (14-16), and with TSH at both extremities of the reference range (e.g. higher risk of cardiovascular 312 
disease with high TSH/low FT4, and higher risk of fractures, osteoporosis, and dementia with low TSH/high 313 
FT4) (9, 13). There may be optimal values of thyroid function tests within the reference range. 314 
Second, similar to previous studies showing stronger association of adverse outcomes with FT4 than TSH (37, 315 
38), FT4 was associated with hip, any and non-vertebral fracture, while TSH was associated only with hip 316 
fracture. TSH and thyroid hormones may act differently on peripheral organs, including bones: TSH may act on 317 
osteoblasts and osteoclasts via specific receptors (3), while thyroid hormones may act on target tissues via 318 
nuclear receptors controlled locally by deiodinases (3, 39, 40). This may explain why TSH and FT4 are 319 
associated with different fracture types. FT4 may therefore help evaluate osteoporosis and fracture risk, which is 320 
now usually done with the World Health Organization FRAX score, but future studies should determine if 321 
adding FT4 improves clinical accuracy of this score. Of note, FT4 was not significantly associated with 322 
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vertebral fracture. One explanation may be that FT4 acts differently on vertebral bone. It may however also be 323 
due to lack of power, as we could include about ten times fewer vertebral than other fractures (Table 3). 324 
We may have expected a stronger association of fracture risk with TSH and FT4, respectively, after excluding 325 
participants with thyroid medication at baseline, but the risk was only slightly increased, probably because of 326 
the low number of participants with thyroid medication at baseline (N=1897, 3%). 327 
In conclusion, analyzing individual data of 61,959 adults from thirteen large prospective cohorts, we found that 328 
TSH at the lower extremity of the reference range was associated with higher risk of hip fractures, and high FT4 329 
with higher risk of hip, any, and non-vertebral fractures. Our findings may help refine the current definition of 330 
optimal thyroid function. Meanwhile, clinicians should be aware that lower TSH and higher FT4, even within 331 
the reference range, are associated with an increased risk of hip fracture.  332 
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Table 1. Study population and baseline characteristics of the participants in the 13 included studies (n=61,959) 
 
Study name,  
place 
Description of  
study population 
Number of 
participants 
Age, 
median 
(range)* 
Women, 
 No. (%) 
TSH, 
median, 
mIU/L 
Thyroid 
medication at 
baseline, No. 
(%)†,‡ 
Thyroid 
medication 
during follow-
up, No. (%)†,§ 
Start of 
follow-up, 
year 
Duration of 
follow-up,  
median (IQR), 
years|| 
Person-
years 
Busselton Health 
Study, Australia (29)  Adults 1,907 
51  
(18-90) 919 (48.2) 1.42 10 (0.5) 15 (0.8) 1981 20.0 (17.6-20.0) 33,281 
CHS, USA (4 
communities) (25)  
Adults with 
Medicare  
eligibility 
2,853 71  (65-100) 1,694 (59.4) 2.03 145 (5.1) 299 (10.5) 1989-1990 12.9 (7.5-18.9) 36,466 
EPIC-Norfolk Study, 
England (30)  
Adults aged  
45-79y 11,986 
58  
(40-78) 6,365 (53.1) 1.70 275 (2.3) NA 1995-1998 12.4 (11.7-13.3) 142,951 
Health ABC Study, 
USA (4 communities) 
(14)  
Adults aged  
70-79y with 
Medicare 
eligibility 
2,347 74  (69-81) 1,165 (49.6) 1.99 177 (7.5) 383 (13.9) 1997 12.7 (8.1-13.2) 24,794 
HUNT Study, 
Norway (31) ¶ Adults 31,388 
57  
(19-99) 21,186 (67.5) 1.60 999 (3.2) NA 1995-1997 12.2 (11.6-12.8) 345,517 
InCHIANTI Study, 
Italy (17)  
 
Adults aged ≥65y 1,066 71  (21-102) 590 (55.3) 1.38  17 (1.6) 28 (2.6) 1998 9.1 (7.8-9.3) 8,562 
Leiden 85-Plus Study, 
The Netherlands (32) Adults aged 85y 456 
85  
(85-85) 293 (64.3) 1.66 6 (1.3) 11 (2.4) 1997-1999 4.8 (2.2-8.1) 2,411 
MrOS, USA (6 
clinical centers) (10) Men aged ≥65y 1,410 
73  
(65-99) All men 1.97 83 (5.9) 98 (6.9) 2000-2002 11.1 (8.1-11.8) 13,568 
OPUS, Germany, 
France, UK (5)** 
Women aged  
20-80y 1,205 
63  
(20-80) All women 0.96 0 (0.0) NA 1999-2001 6.0 (5.8-6.3) 7,179 
PROSPER, Ireland, 
Scotland, The 
Netherlands (33) 
Older adults at 
high 
cardiovascular risk 
5,124 75  (69-83) 2,527 (49.3) 1.75 135 (2.6) 163 (3.2) 1997-1999 3.2 (3.0-3.5) 15,833 
Rotterdam Study, The 
Netherlands (34) Adults aged ≥55y 1,611 
68  
(55-93) 957 (59.4) 1.54 21 (1.3) NA 1989-1992 15.2 (10.4-16.2) 21,130 
Sheffield Study, 
England (26) 
 
Women aged  
50-85y 291 
63  
(50-86) All women 2.00 2 (0.7) 9 (3.1) 1990-1991 10.0 (5.5-10.1) 2,301 
SOF, USA (4 clinical 
centers) (19)†† Women >65y 314 
71  
(65-88) All women 1.50 15 (4.8) NA 1986-1998 14.3 (9.8-19.8) 4,433 
Overall 13 cohorts 61,959 64  (18-102) 37,506 (60.5) 1.60 1,885 (3.1) 831 (5.5) 1981-2002 
12.1  
(8.5-12.9) 
659,059 
‡‡ 
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Abbreviations: CHS, Cardiovascular Health Study; EPIC, European Prospective Investigation of Cancer; Health ABC, Health, Aging and Body Composition; HUNT, Nord-Trøndelag 
Health Study; InCHIANTI, Invecchiare in Chianti; IQR, interquartile range; MrOS, Osteoporotic Fractures in Men Study; No., number; OPUS, Osteoporosis and Ultrasound Study; 
PROSPER, Prospective Study of Pravastatin in the Elderly at Risk; SOF, Study of Osteoporotic Fractures; TSH, thyroid-stimulating hormone; UK, United Kingdom; USA, United States of 
America; y, years.  
* We excluded participants younger than 18y. 
† Thyroid medication was defined as thyroxine or anti-thyroid medication. 
‡ Data on thyroid medication at baseline was missing for 255 participants in the HUNT Study, 59 participants in the MrOS, one participant in the Rotterdam Study, four participants in the 
SOF and seven participants in the Health ABC Study. 
§ Data on thyroid mediation at follow-up was missing for 243 participants in the MrOS, 96 participants in the InCHIANTI Study, 45 participants in the Sheffield Study, and all participants 
in the HUNT Study, EPIC-Norfolk Study, Rotterdam Study, OPUS and SOF. 
|| Duration of follow-up was defined as the maximum duration of follow-up that was available, i.e. the time to the first hip (or any if unavailable) fracture or censor date/death. 
¶ We included participants excluded from the original article of the HUNT Study (participants <40y, with previous fracture and/or with previous thyroid disease), which explains the 
different number of the sample. 
** We included only the thyroid hormone sub-study of the OPUS, which excluded participants on thyroid medication. 
†† We included only a subsample of the SOF, i.e., the participants with TSH measurement at baseline. 
‡‡ It was calculated as time to hip fracture; for the PROSPER, it was calculated as time to any fracture, since data on hip fracture was unavailable.	 	
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Table 2: Sensitivity analyses for the risk of hip fracture according to thyroid-stimulating hormone and free thyroxine  
 
 Analysis by TSH category* Analysis by SD increase in FT4† 
No. of events/ 
participants 
Hazard ratio 
(95% CI)‡ 
No. of events/ 
participants 
Hazard ratio 
(95% CI)§ 
Main analysis 610/13,390 1.25 (1.05-1.49) 542/20,633 1.24 (1.12-1.37) 
  Medication use 
 Excluding participants with thyroid medication at baseline|| 557/12,728 1.28 (1.06-1.53) 526/20,158 1.26 (1.13-1.40) 
 Excluding participants with thyroid-altering medication at baseline¶ 542/12,396 1.28 (1.07-1.55) 506/19,679 1.26 (1.13-1.40) 
 Excluding participants with anti-fracture medication at baseline** 605/12,739 1.27 (1.07-1.52) 539/20,563 1.24 (1.12-1.38) 
  Definition of fracture 
  Including only studies with formal fracture adjudication†† 496/12,048 1.31 (1.06-1.60) 416/17,913 1.21 (1.07-1.36) 
  Other  
  Excluding one study with loss to follow-up >5%‡‡ 606/12,748 1.26 (1.05-1.50) 536/19,463 1.24 (1.11-1.37) 
  BMD 
  Further adjusting for femoral neck BMD at baseline§§ 94/2,020 1.68 (1.08-2.61)|||| 142/4,147 1.22 (1.01-1.47) 
Abbreviations: BMD, bone mineral density; CHS, Cardiovascular Health Study; CI, confidence interval; EPIC, European Prospective Investigation of Cancer; 
FT4, free thyroxine; Health ABC, Health, Aging and Body Composition; HUNT, Nord-Trøndelag Health Study; InCHIANTI, Invecchiare in Chianti; MrOS, 
Osteoporotic Fractures in Men Study; No., number; OPUS, Osteoporosis and Ultrasound Study; PROSPER, Prospective Study of Pravastatin in the Elderly at 
Risk; SD, standard deviation; SOF, Study of Osteoporotic Fractures; TSH, thyroid-stimulating hormone. 
All analyses were adjusted for age (as a continuous variable) and sex. Data for hip fractures were available for 12 cohorts (all but PROSPER). 
* We present a selected analysis for the TSH category 0.45-0.99mIU/L compared with the reference category (TSH 3.50-4.99mIU/L). No. are for participants 
in these both TSH categories only. 
† FT4 was measured in all studies but the SOF and the Health ABC Study (FT4 not measured in participants with TSH within reference range). 
‡ Hazard ratios are for TSH 0.45-0.99mIU/L, compared with the reference group 3.50-4.99mIU/L. 
§ Hazard ratios are per one standard deviation increase in FT4. 
|| Thyroid medication was defined as thyroxine or anti-thyroid medication. 
¶ Thyroid-altering medication included oral corticosteroid, amiodarone, iodine, thyroxine, or anti-thyroid medication. 
** Anti-fracture medication was defined as bisphosphonate, calcitonin, selective estrogen receptor modulator, or parathyroid hormone. 
†† EPIC-Norfolk Study, HUNT Study, InCHIANTI Study, MrOS, OPUS, Rotterdam Study, Sheffield Study, Health ABC Study, and SOF (Health ABC Study 
and SOF only in the TSH analysis). 
‡‡ OPUS. 
§§ Femoral neck BMD at baseline was available in following studies: CHS, MrOS, Rotterdam Study, Sheffield Study, OPUS, Health ABC Study. 
|||| Participants within the TSH category 3.50-4.49mIU/L had lower femoral neck BMD at baseline than participants within the TSH category 0.45-1.50mIU/L 
(mean [SD]: 0.77g/cm2 [0.16] versus 0.79 g/cm2 [0.15], respectively, P = 0.002), which explains the higher hazard ratio after adjusting for femoral neck BMD 
at baseline. 
 
 
 
Table 3. Sensitivity and stratified analyses for the risk of any, non-vertebral, and vertebral fractures, per one standard deviation increase in free thyroxine 
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 Any fracture* Non-vertebral fracture† Vertebral fracture‡ 
No. of 
events/ 
participants 
Hazard ratio 
(95% CI) 
No. of 
events/ 
participants 
Hazard ratio 
(95% CI) 
No. of events/ 
participants 
Hazard ratio 
(95% CI) 
Main analysis 1,629/22,977 1.08 (1.02-1.15) 1,273/19,101 1.10 (1.03-1.18) 129/17,711 1.06 (0.86-1.30) 
  SENSITIVITY ANALYSES 
  Medication use 
 Excluding participants with thyroid medication at baseline§ 1,552/22,440   1.09 (1.02-1.16) 1,240/18,697 1.14 (1.06-1.23) 125/17,309 1.08 (0.86-1.37) 
 Excluding participants with thyroid-altering medication at 
 baseline|| 1,537/21,976 1.09 (1.02-1.15) 1,200/18,256 1.11 (1.03-1.19) 125/16,868 1.07 (0.86-1.32) 
 Excluding participants with anti-fracture medication at baseline¶ 1,622/22,927 1.08 (1.02-1.15) 1,263/19,038 1.10 (1.03-1.18) 127/17,666 1.05 (0.85-1.29) 
  Definition of fracture 
  Including only studies with formal fracture adjudication** 1,026/15,805 1.11 (1.02-1.19) 1,111/17,208 1.11 (1.03-1.19) 113/15,806 1.07 (0.86-1.32) 
  Including only studies with most uniform definition of fracture†† 1,155/19,728 1.06 (0.99-1.14) 685/14,461 1.08 (0.98-1.19) 65/14,462 1.10 (0.83-1.47) 
  Other  
 Further adjusting for BMI, smoking status, and diabetes mellitus 1,591/22,536 1.21 (1.00-1.46) 1,140/17,562 1.09 (1.01-1.18) 126/17,290 1.03 (0.83-1.27) 
 Excluding studies with loss of follow-up rate >5% NA NA 1,174/17,981 1.13 (1.04-1.22) NA NA 
  BMD 
  Further adjusting for lumbar spine BMD at baseline‡‡ NA NA NA NA 39/1,399 0.96 (0.68-1.36) 
  Further adjusting for whole body BMD at baseline§§ 183/1,399 0.89 (0.75-1.04) NA NA NA NA 
  STRATIFIED ANALYSES 
  Stratified for sex  
 Women 1,013/11, 321 1.11 (1.03-1.19) 827/10,075 1.10 (1.01-1.20) 62/8,679 1.12 (0.83-1.51) 
 Men 616/11,656 1.05 (0.95-1.15) 446/9,026 1.08 (0.96-1.22) 67/9,032 1.00 (0.75-1.33) 
P-value for interaction NA 0.39 NA 0.79 NA 0.61 
  Stratified for age  
 <75 years at baseline 1,041/18,367 1.10 (1.02-1.19) 955/17,144 1.10 (1.02-1.20) 87/15,917 0.96 (0.74-1.25) 
≥75 years at baseline 588/4610 1.06 (0.96-1.16) 318/1,957 1.10 (0.97-1.25) 42/1,794 1.25 (0.88-1.76) 
P-value for interaction NA 0.47 NA 0.99 NA 0.25 
  Stratified for duration of follow-up  
 <5 years  446/5,920 1.04 (0.93-1.15) 47/888 0.82 (0.59-1.14) 7/888 0.60 (0.26-1.37) 
  ≥5 years  1,183/17,057 1.09 (1.02-1.18) 1,226/18,213 1.10 (1.03-1.18) 122/16,823 1.07 (0.87-1.33) 
P-value for interaction NA 0.39 NA 0.07 NA 0.18 
 
Abbreviations: BMD, bone mineral density; BMI, body mass index; CI, confidence interval; EPIC, European Prospective Investigation of Cancer; FT4, free thyroxine; 
Health ABC, Health, Aging and Body Composition; InCHIANTI, Invecchiare in Chianti Study; MrOS, Osteoporotic Fractures in Men Study; NA, not appropriate; No., 
number; OPUS, Osteoporosis and Ultrasound Study; PROSPER, Prospective Study of Pravastatin in the Elderly at Risk; SD, standard deviation; SOF, Study of 
Osteoporotic Fractures; TSH, thyroid-stimulating hormone. 
All analyses were adjusted for age (as a continuous variable) and sex; FT4 was measured in all studies but SOF and Health ABC Study (FT4 not measured in participants 
with TSH within the reference range). 
Hazard ratios are per one standard deviation increase in FT4. 
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* Data on any fractures were available for 7 studies (MrOS, EPIC-Norfolk Study, InCHIANTI Study, Leiden 85-Plus Study, PROSPER, Rotterdam Study, Busselton 
Health Study). 
† Data on non-vertebral fractures were available for 7 studies (MrOS, EPIC-Norfolk Study, InCHIANTI Study, Rotterdam Study, Busselton Health Study, Sheffield Study, 
OPUS). 
‡ Data on vertebral fractures were available for 5 studies (MrOS, EPIC-Norfolk Study, InCHIANTI Study, Rotterdam Study, Busselton Health Study). Vertebral fracture 
was defined as a clinical symptomatic dorsal or lumbar fracture. 
§ Thyroid medication was defined as thyroxine or anti-thyroid medication. 
|| Thyroid-altering medication included oral corticosteroid, amiodarone, iodine, thyroxine, or anti-thyroid drug. 
¶ Anti-fracture medication was defined as bisphosphonate, calcitonin, selective estrogen receptor modulator, or parathyroid hormone. 
** EPIC-Norfolk Study, InCHIANTI Study, MrOS, OPUS, Rotterdam Study, Sheffield Study. 
†† EPIC-Norfolk Study, InCHIANTI Study, Leiden 85-Plus Study, MrOS, PROSPER. 
‡‡ Lumbar spine BMD was available in MrOS only. 
§§ Whole body BMD was available in MrOS only. 
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Figure 1. Risk of hip fracture according to thyroid-stimulating hormone categories 0 
 1 
 2 
 3 
Abbreviations: CI, confidence interval; HR; hazard ratio; No., number; TSH, thyroid-stimulating hormone. 4 
Data on hip fractures were available for 12 studies (all except PROSPER). 5 
 6 
 7 
  8 
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Figure 2. Risk of hip fracture per one standard deviation increase in free thyroxine, overall and stratified by sex, age, and duration of follow-up 10 
 11 
 12 
 13 
Abbreviations: CI, confidence interval; FT4, free thyroxine; Health ABC, Health, Aging and Body Composition; HR; hazard ratio; No., Number; SOF, Study of 14 
Osteoporotic fractures, TSH, thyroid-stimulating hormone. 15 
The analysis stratified for sex was adjusted for age. All other analyses were adjusted for age (as a continuous variable) and sex. 16 
FT4 was measured in all studies but SOF and Health ABC Study (FT4 not measured in participants with TSH within the reference range).  17 
Data on hip fractures were available for 10 studies with measured FT4 (all except PROSPER). 18 
